Press Releases Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
0.768 ^USD	-0.56%		-6.00%	-18.94%

May. 09	Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 14	Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update	May. 09	BU
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	May. 06	BU
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	Apr. 08	BU
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update	Mar. 14	BU
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	Mar. 08	BU
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 28	BU
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis	Feb. 26	BU
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)	Dec. 04	PR
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference	Nov. 21	BU
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	BU
Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 09	AQ
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	Nov. 03	BU
KEZAR ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)	23-10-10	AQ
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-10	AQ
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	23-10-09	BU
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer	23-10-03	BU
Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets	23-09-21	AQ
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia	23-09-20	BU
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences	23-08-31	BU
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-10	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Press Releases

Filters